Skip to main content
Erschienen in: Clinical Rheumatology 3/2021

19.08.2020 | Original Article

Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis?

verfasst von: Julián E. Barahona-Correa, Jorge Flórez-Suárez, Paola Coral-Alvarado, Paul Méndez-Patarroyo, Gerardo Quintana-López

Erschienen in: Clinical Rheumatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background/purpose

Adequate control of disease activity in rheumatoid arthritis (RA) depends, to a great extent, on the access to a rheumatologist. This study aimed to compare the disease outcomes of patients with RA, based on their healthcare regime affiliation.

Methods

A retrospective observational study of Colombian patients with RA in three outpatient services of different regimes: Contributory (CR, workers and their families with a monthly income above a yearly defined threshold, approximately US$ 220, who allocate a percentage of their income to financing the national health fund and to get access to healthcare services), subsidized (SR, a vulnerable population with a monthly income below the threshold, who have access to healthcare through the national health fund; comparable to the USA Medicaid population), and an excellence clinical care center (C3, access to specialized care, regardless of their healthcare affiliation regime). Data were collected from clinical records for 2 years of follow-up and included demographics, lag times between appointments, and time in high disease activity. We used the Mantel-Cox test for the analysis of time to remission/low disease activity.

Results

A total of 240 patients were included (80 patients per regime). At the start of follow-up, mean age was 53.7 years; 21.6% of patients were men; 79.6% of patients had established RA; 72.9% of patients had high disease activity. Patients in the CR had longer lag times between scheduled appointments (p < 0.0001). During follow-up, SR had the highest proportion of patients with high disease activity. Survival curve analysis showed no significant difference between SR and CR groups (p = 0.2903), but was significantly different compared with the C3 group (p < 0.0001). Median survival in high disease activity was greater in the SR group (293 days), followed by CR (254 days), and finally by C3 (64 days).

Conclusion

Patients that were treated in the excellence clinical care center had better outcomes when compared with other regimes. These data support that healthcare regime may influence disease outcome in patients with RA.
Key Points
Prompt access to healthcare in patients with rheumatoid arthritis is pivotal for an adequate control of the disease, for timely adjustment of treatment, and to reduce both the societal burden of the disease and its impact on individual well-being.
As an example of “structural iatrogenesis,” healthcare regime affiliation appears to influence disease outcomes in patients with rheumatoid arthritis, in whom differences between regimes are observed. The most vulnerable patients appear to experience the worst outcomes.
Excellence clinical care centers for patients with rheumatoid arthritis should be implemented as an alternative to counteract structural healthcare barriers and as an approach to improve clinical outcomes through a tighter disease control.
Literatur
2.
Zurück zum Zitat Londoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, Ballesteros JG, Baquero R, Forero E, Cardiel M, Saldarriaga E, Vásquez A, Arias S, Valero L, González C, Ramírez J, Toro C, Santos AM (2018) Prevalence of rheumatic disease in Colombia according to the Colombian Rheumatology Association (COPCORD) strategy. Prevalence study of rheumatic disease in Colombian population older than 18 years. Rev Colomb Reumatol 25:245–256. https://doi.org/10.1016/j.rcreu.2018.08.003CrossRef Londoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, Ballesteros JG, Baquero R, Forero E, Cardiel M, Saldarriaga E, Vásquez A, Arias S, Valero L, González C, Ramírez J, Toro C, Santos AM (2018) Prevalence of rheumatic disease in Colombia according to the Colombian Rheumatology Association (COPCORD) strategy. Prevalence study of rheumatic disease in Colombian population older than 18 years. Rev Colomb Reumatol 25:245–256. https://​doi.​org/​10.​1016/​j.​rcreu.​2018.​08.​003CrossRef
6.
Zurück zum Zitat Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, de Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699. https://doi.org/10.1136/annrheumdis-2019-216655 Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, de Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699. https://​doi.​org/​10.​1136/​annrheumdis-2019-216655
8.
Zurück zum Zitat (2015) Health and health care in Colombia. In: OECD Reviews of Health Systems: Colombia 2016. OECD, pp 37–72 (2015) Health and health care in Colombia. In: OECD Reviews of Health Systems: Colombia 2016. OECD, pp 37–72
12.
Zurück zum Zitat Santos-Moreno P, Caballero-Uribe CV, Cardiel MH, Galarza-Maldonado C, Massardo L, Pineda C, Soriano E, Castro CA, Villarreal L, Buitrago D (2019) A consensus position paper from REAL-PANLAR Group about the methodological approach for the accreditation process of centers of excellence in rheumatoid arthritis in Latin America. J Clin Rheumatol 25:54–58. https://doi.org/10.1097/RHU.0000000000000773CrossRefPubMed Santos-Moreno P, Caballero-Uribe CV, Cardiel MH, Galarza-Maldonado C, Massardo L, Pineda C, Soriano E, Castro CA, Villarreal L, Buitrago D (2019) A consensus position paper from REAL-PANLAR Group about the methodological approach for the accreditation process of centers of excellence in rheumatoid arthritis in Latin America. J Clin Rheumatol 25:54–58. https://​doi.​org/​10.​1097/​RHU.​0000000000000773​CrossRefPubMed
13.
Zurück zum Zitat Ministerio de Salud y Protección Social (2014) Guía de práctica clínica para la detección temprana, diagnóstico y tratamiento de la artritis reumatoide Ministerio de Salud y Protección Social (2014) Guía de práctica clínica para la detección temprana, diagnóstico y tratamiento de la artritis reumatoide
14.
Zurück zum Zitat England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, O'Dell JR, Ranganath VK, Limanni A, Suter LG, Michaud K (2019) 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res 71:1540–1555. https://doi.org/10.1002/acr.24042CrossRef England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, O'Dell JR, Ranganath VK, Limanni A, Suter LG, Michaud K (2019) 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res 71:1540–1555. https://​doi.​org/​10.​1002/​acr.​24042CrossRef
15.
Zurück zum Zitat Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715CrossRefPubMed Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://​doi.​org/​10.​1136/​annrheumdis-2016-210715CrossRefPubMed
19.
Zurück zum Zitat Rondón Sepulveda MA (2015) Sample size calculation. In: Ruiz-Morales A, Gómez-Restrepo C (eds) Clinical epidemiology: applied clinical research, 2nd edn. Panamericana, Bogota, Colombia, pp 76–90 Rondón Sepulveda MA (2015) Sample size calculation. In: Ruiz-Morales A, Gómez-Restrepo C (eds) Clinical epidemiology: applied clinical research, 2nd edn. Panamericana, Bogota, Colombia, pp 76–90
20.
Zurück zum Zitat Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomšič M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96. https://doi.org/10.1136/ard.2008.105197CrossRefPubMed Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomšič M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96. https://​doi.​org/​10.​1136/​ard.​2008.​105197CrossRefPubMed
21.
Zurück zum Zitat Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450. https://doi.org/10.1002/art.10308CrossRefPubMed Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450. https://​doi.​org/​10.​1002/​art.​10308CrossRefPubMed
25.
Zurück zum Zitat Santos-Moreno P, Alvis-Zakzuk NJ, Villarreal-Peralta L, Carrasquilla-Sotomayor M, Paternina-Caicedo A, Alvis-Guzmán N (2018) A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia. Rheumatol Int 38:499–505. https://doi.org/10.1007/s00296-017-3903-2CrossRefPubMed Santos-Moreno P, Alvis-Zakzuk NJ, Villarreal-Peralta L, Carrasquilla-Sotomayor M, Paternina-Caicedo A, Alvis-Guzmán N (2018) A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia. Rheumatol Int 38:499–505. https://​doi.​org/​10.​1007/​s00296-017-3903-2CrossRefPubMed
29.
Zurück zum Zitat Arora S, Nika A, Trupin L, Abraham H, Block J, Sequeira W, Yazdany J, Jolly M (2018) Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic? Arthritis Care Res 70:1771–1777. https://doi.org/10.1002/acr.23569CrossRef Arora S, Nika A, Trupin L, Abraham H, Block J, Sequeira W, Yazdany J, Jolly M (2018) Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic? Arthritis Care Res 70:1771–1777. https://​doi.​org/​10.​1002/​acr.​23569CrossRef
33.
Zurück zum Zitat Raza K, Stack R, Kumar K, Filer A, Detert J, Bastian H, Burmester GR, Sidiropoulos P, Kteniadaki E, Repa A, Saxne T, Turesson C, Mann H, Vencovsky J, Catrina A, Chatzidionysiou A, Hensvold A, Rantapää-Dahlqvist S, Binder A, Machold K, Kwiakowska B, Ciurea A, Tamborrini G, Kyburz D, Buckley CD (2011) Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis 70:1822–1825. https://doi.org/10.1136/ard.2011.151902CrossRefPubMed Raza K, Stack R, Kumar K, Filer A, Detert J, Bastian H, Burmester GR, Sidiropoulos P, Kteniadaki E, Repa A, Saxne T, Turesson C, Mann H, Vencovsky J, Catrina A, Chatzidionysiou A, Hensvold A, Rantapää-Dahlqvist S, Binder A, Machold K, Kwiakowska B, Ciurea A, Tamborrini G, Kyburz D, Buckley CD (2011) Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis 70:1822–1825. https://​doi.​org/​10.​1136/​ard.​2011.​151902CrossRefPubMed
Metadaten
Titel
Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis?
verfasst von
Julián E. Barahona-Correa
Jorge Flórez-Suárez
Paola Coral-Alvarado
Paul Méndez-Patarroyo
Gerardo Quintana-López
Publikationsdatum
19.08.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 3/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05347-2

Weitere Artikel der Ausgabe 3/2021

Clinical Rheumatology 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.